WHATNEXT partner website Patient Worthy recently published a story about the role of histone deacetylase (HDAC) inhibitors in the treatment of pancreatic cancer, one of the most deadly forms of cancer.
Author James Moore writes:
The study evaluated the effect of histone deacetylase (HDAC) inhibitors on the activity of fibroblasts. HDAC plays a vital role in making changes to the 3D structure of DNA within a cell. An HDAC inhibitor would prevent a cell from making major changes to its DNA structure and behavior—such as the erratic, out of control growth of a cancer cell.
In a test on isolated cells in a lab setting, HDAC inhibitors prevent fibroblasts from activating and entering a tumor-supportive state. In a pancreatic cancer mouse model, an HDAC inhibitor called entinostat reduced fibroblast activation at the tumor site and slowed growth of the tumor.
To learn more about this subject, check out the full article here.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. Patient Worthy and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
cancer treatment digestive system cancer endocrine system cancer pancreatic cancer research treatment
Last modified: April 10, 2024
